Employee stock options in Life Sciences: expected 2027 changes and how to prepare

November 18, 2026
•
5 min read
By Lars Ottevanger
Employee stock options in Life Sciences: expected 2027 changes and how to prepare
Table of content
TLDR
  • 2027 Tax Cut: The Dutch House of Representatives passed the Fiscal Incentives for Start-ups and Scale-ups Act, lowering the effective tax rate on employee stock options from 49.5% to ~32% (in line with founders' Box 2 rate).
  • Win-Win for Talent & Startups: Employees keep significantly more net upside upon a successful exit while company costs remain unchanged - making equity a stronger retention tool in cash-strapped sectors like Life Sciences.
  • Pending Senate Approval: The bill still awaits a Senate vote (expected to pass), so avoid irreversible decisions until it becomes final.
  • Prepare Flexibly Now: Set up a SAR plan today with a clear conversion clause so it can be smoothly converted into a stock option plan once the law takes effect and an RVO decision is obtained.
  • Plan Early & Consider Cross-Border Rules: Define your equity pool before talking to investors, and seek specialized tax advice if you have international employees working across multiple countries.
  • ‍

    As a startup in the life sciences sector, you need an outstanding team. But paying a competitive salary is often difficult in the early stages. The tool that life sciences founders in the Netherlands have been using for years to bridge that gap is an option or SAR plan. While this solves the problem on paper, in practice it results in employees paying a relatively high amount of tax upon exercise. Sometimes even nearly half of what they receive. The regulations surrounding employee stock options are expected to change in 2027.

    On November 12, 2026, the House of Representatives passed the Wet fiscale stimulering start-ups en scale-ups (Fiscal Incentives for Start-ups and Scale-ups Act), part of the 2027 Tax Plan, by a large majority of 102 votes. The Senate has yet to vote on the bill, but it is expected to receive sufficient support. 

    In this article, Lars Ottevanger, partner and director of Life Sciences at F.INSTITUTE, Thijs de Wilde, partner at Novera Tax Lawyers, and Max Luijkx, attorney at Axon Lawyers, explain exactly what will change and how you can start preparing wisely now, before the law officially takes effect.

    Amendment to employee stock option regulations adopted, effective 2027

    The bill, which significantly reduces the tax burden on employee stock options at startups and scale-ups in the innovative sector, was adopted by the Dutch House of Representatives (Tweede Kamer) on November 12, 2026. Once the Dutch Senate (Eerste Kamer) also approves it, this will change the way Life Sciences companies attract and retain talent.

    The problem is that the reward you offer your talent is worth half as much as it looks

    Retaining talent in Life Sciences is fundamentally different from other sectors. Companies sometimes operate for ten years without generating revenue. Competition for top talent is fierce, and funding is scarce. An option or stock program is therefore not a luxury but a necessity. However, the current system does not work in the employee’s favor.

    “Employee stock options and SARs were actually both taxed at 49.5%,” explains Thijs de Wilde. “That means you’re handing over half of the success to the tax authorities.” This makes the incentive less attractive than it seems. For an employee who takes a risk by consciously accepting a lower salary, that’s a harsh reality with little to show for it.

    The result is an industry that undermines its own growth potential. Precisely in the type of companies that depend on talented people willing to work for less than a market-rate salary, those employees also end up handing over half of their compensation to the tax authorities if the arrangement proves successful.

    What’s changing in 2027: effective tax rate from 49.5% to 32%

    This bill aims to correct that. If it passes, the gain on employee stock options will no longer be taxed at 49.5%, but at an effective rate of approximately 32%.

    “This brings the tax burden on employee stock options roughly in line with the highest Box 2 rate that applies to founders and other shareholders,” says De Wilde. The underlying rationale is clear: if a founder and an employee both take risks and both contribute to the company’s success, it is difficult to justify why they are taxed so differently.

    The result is clear. An employee who cashes in his stock options following a successful exit ends up with significantly more money in the end. For founders, little changes financially: the costs for the organization remain essentially the same. 

    The advantage lies entirely with the employee, which actually makes the option a stronger incentive. “We expect the market to really jump on the option plan,” says De Wilde.

    “Employee stock options and SARs are currently both taxed at 49.5%. But this means employees are handing over half of the company’s success to the tax authorities.”

    Thijs de Wilde, Novera Tax Lawyers

    Status: passed by the House of Representatives; pending in the Senate

    Although the bill has now been passed by the House of Representatives, some caution is still warranted. After all, it has yet to be debated in the Senate, so the legislation is not yet final.

    “It’s a positive development that there’s growing attention toward a more tax-friendly treatment of employee participation schemes,” says Thijs de Wilde. “At the same time, we shouldn’t jump the gun. It’s wise to wait for the Senate’s deliberations before companies make final decisions based on the new regulations.”

    Don’t wait: build flexibility in now

    That doesn’t mean companies have to sit completely idle in the meantime. For companies considering employee participation, it may be wise to start factoring in the potential new regulations. In doing so, it’s especially important to maintain sufficient flexibility.

    “If you build enough flexibility into your SAR plan, you can include a provision allowing you to convert it into an option plan later,” advises Max Luijkx. “That means you can set up a SAR plan today for employees you want to retain, with the explicit option to convert that plan as soon as the law is definitively enacted.”

    From a legal perspective, this can be a practical approach, but it also places demands on the quality of the documentation. He continues: “Document everything in a clear and understandable way from the very beginning. Ambiguity is the absolute worst thing that can happen to you.”

    A SAR plan set up now that doesn’t allow sufficient flexibility for conversion could become problematic later, both legally and fiscally. Those who build in sufficient flexibility will be ready as soon as the law permits it and an RVO decision has been obtained.

    “Build enough flexibility into your SAR plan by specifying that you can convert it to a stock option plan later, once the law has been definitively enacted.”

    Max Luijkx, Axon Lawyers

    When should you start with an equity plan?

    The point at which an option or SAR plan becomes relevant depends on your company’s growth stage. But there is a recognizable pattern.

    “As soon as you, as an entrepreneur, see growth in your team and realize that certain roles need to remain permanently on staff, such as a C-suite executive, a medical director, or a technical officer, you try to attract them with an attractive package of salary plus additional benefits,” says Lars Ottevanger. “Engagement through employee ownership is always part of that overall strategy.”

    From a financial perspective, the timing is also relevant to the broader discussion about how you structure your business. He continues: “The questions I often ask my clients are: when you’re setting up a financial plan, how do you want to reward people? How much are you giving away? And which instruments do you use: salary, stock options, or a combination? It’s best to have that conversation before you talk to an investor, not after.”

    “When setting up your finance structure, think about how you will reward your people. How much are you giving away? And which instruments do you use: salary, stock options, or a combination? Include employee engagement through equity participation as part of that overall picture.”

    Lars Ottevanger, F.INSTITUTE

    International employees add an extra layer of complexity

    If you have employees in multiple countries, things get more complex. Not just from a tax perspective, but also from a legal one.

    “It’s extremely important where someone lives, where they work, and where decisions are made,” explains De Wilde. “Based on that, you can determine whether or not a particular country has the authority to tax.” If an employee lives partly in Italy and works partly in the Netherlands, that determines how taxes are allocated. And that has direct implications for how you structure an equity participation plan.

    Life Sciences companies often have international research teams, partnerships with foreign institutions, and management spread across multiple countries. This complexity requires advisors who not only know the tax rules but also understand the structural makeup of a biotech or medtech company.

    Employee stock options in 2027: here’s how to approach it

    The legislative change appears set to take effect in 2027 now that the House of Representatives has voted and the Senate is expected to follow suit. Now is the time to act: set up a flexible SAR plan with a conversion clause and get your option pool and allocation policy in order. Then keep an eye on the Senate’s deliberations for the final go-ahead.

    Want to stay up to date on developments regarding employee stock options and all the tax, legal, and financial issues affecting life sciences companies? Follow Lars Ottevanger, Thijs de Wilde, and Max Luijkx on LinkedIn.

    A fractional CFO for your Life Sciences company?

    If you’d like to explore this topic further and discover what F.INSTITUTE can do for your organization, please contact us. We’d be happy to discuss your goals.

    ‍